Search Results
Your search for The ASCO matches 21433 pages
Showing 13351 - 13400Renowned Hematologist Mojtaba Akhtari, MD, Reflects on a New Era in Treating Blood Cancers
The nationally recognized hematologist-oncologist Mojtaba Akhtari, MD, was born and reared in Tehran, Iran. “In my early years, I had a couple of cousins who were medical students. When I visited them in their homes, I was fascinated with the images in their medical text books. I would flip the...
Lack of Access to Transfusions Limits Hospice Use by Patients With Blood Cancer
A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies. The findings, published by Odejide et al in Cancer, help explain...
ASCO and CAP Invite Comment on Focused Update to HER2 Testing Guideline in Breast Cancer
Draft recommendations as part of a focused update to the ASCO/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017. For patients with invasive breast...
In Remembrance of H. Jean Khoury, MD, FACP
Winship Cancer Institute of Emory University is mourning the loss of an esteemed colleague: H. Jean Khoury, MD, FACP, died on Monday, May 22, after a year spent battling cancer. His many colleagues and friends remember him as an outstanding physician, researcher, and educator, and a respected and...
ASCO Presidents Through the Years
2016–2017 Daniel Hayes, MD 2015–2016 Julie Vose, MD, MBA 2014–2015 Peter Paul Yu, MD, FACP 2013–2014 Clifford A. Hudis, MD, FACP 2012–2013 Sandra M. Swain, MD 2011–2012 Michael P. Link, MD 2010–2011 George W. Sledge, Jr, MD 2009–2010 Douglas W. Blayney, MD 2008–2009 Richard...
ASCO President, Bruce E. Johnson, MD, FASCO, Participates in Key Research With EGFR Mutation in Lung Cancer
Bruce E. Johnson, MD, FASCO, 2017–2018 ASCO President, was born in St. Peter, Minnesota, and grew up on a rural dairy farm. “Neither of my parents had college degrees, but working on a dairy farm with them gave me a solid work ethic. I was working outside on the farm before I was 10 years old. In...
Impact of Proposed Cuts to NIH Budget: More Than Just About Cancer
If enacted, the proposed budget reduction of $5.8 billion to the National Institutes of Health (NIH) will slow research, deprive patients afflicted with cancer of hope, and deliver a devastating blow to our science workforce and the Commonwealth of Pennsylvania. This proposed reduction directly...
OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases
Bisphosphonates were first synthesized more than a century ago, with their initial usage restricted to a range of industrial processes until their potential clinical relevance was appreciated in the late 1960s.1 Then, following development for the treatment of osteoporosis and Paget’s disease of...
Weight Management and Physical Activity in Cancer Care: From Research to Real World
Is there enough evidence to support the incorporation of weight management and physical activity interventions into an oncology practice? And if so, what is the best way to do it? The answer to the first question was a resounding yes from oncologists, patient advocates, dietitians, public health...
Tackling the Obesity and Cancer Epidemic
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining...
New Immunotherapy Trial in Breast Cancer at Fox Chase Cancer Center
Patients with some types of breast cancer will have a new clinical trial option at Fox Chase Cancer Center. Medical oncologists Lori Goldstein, MD, and Elias Obeid, MD, MPH, are opening a phase II immunotherapy clinical trial for newly diagnosed, locally recurrent, or metastatic HER2-overexpressing ...
Statement From ASH President on Cancer Drug Parity Act
In response to the introduction of the Cancer Drug Parity Act (H.R. 1409) by Representatives Leonard Lance (R–NJ) and Brian Higgins (D–NY), American Society of Hematology (ASH) President Kenneth C. Anderson, MD, of the Dana-Farber Cancer Institute, issued the following statement: “Oral and...
James Allison, PhD, Named One of TIME ’s 100 Most Influential People in 2017
The University of Texas MD Anderson Cancer Center Chair of Immunology, James Allison, PhD—whose pivotal insight to attack cancer by treating the immune system instead of the tumor revived cancer immunotherapy—has been named to the 2017 TIME 100 Most Influential People. His approach launched a...
Unique Challenges Facing Young Women With Breast Cancer
According to the American Cancer Society, over 252,700 new cases of invasive breast cancer will be diagnosed in 2017, and about 40,610 women will die of their disease. Between 7% and 10% of those new cases will be diagnosed in women younger than age 40, accounting for more than 40% of all cancer...
Sir Richard Peto, FRS, to Receive McGuire Award at 2017 SABCS
Sir Richard Peto, FRS, will receive the William L. McGuire Memorial Lecture Award at the 2017 San Antonio Breast Cancer Symposium (SABCS), to be held December 5–9. The McGuire Award was established in 1992 to honor William L. McGuire, MD, who, along with Charles A. Coltman, MD, founded SABCS in...
Six NY Scientists Win Pershing Square Sohn Prize for Young Investigators in Cancer Research
The Pershing Square Sohn Cancer Research Alliance announced the six winners of the 4th annual Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early-career, New York City–area scientists. Recipients receive $200,000 in funding per year for up...
AACR Honors Mina J. Bissell, PhD, FAACR, With Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) recognized Mina J. Bissell, PhD, FAACR, with the 14th AACR Award for Lifetime Achievement in Cancer Research during the 2017 AACR Annual Meeting in Washington, DC. The AACR Award for Lifetime Achievement in Cancer Research was established in 2004 ...
Clark Chen, MD, PhD, to Join University of Minnesota
The University of Minnesota Medical School has announced the addition of Clark Chen, MD, PhD, as the Lyle French Chair in Neurosurgery and the Head of the University of Minnesota Medical School Department of Neurosurgery. He will assume his new position in August 2017. Dr. Chen is a nationally...
What Is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer?
As the subtleties of metastatic prostate cancer become increasingly recognized, treatment should evolve accordingly, said Jessica M. Clement, MD, Assistant Professor of Medicine at the University of Connecticut Health System and Neag Cancer Center, Farmington. Of particular interest to Dr. Clement ...
Setting His Presidential Course on Making Precision Medicine a Reality for More Patients
Ensuring that all patients with cancer have access to the potential benefits of precision medicine regardless of where they are treated has been a primary goal of Bruce E. Johnson, MD, FASCO, since the concept was first introduced following completion of the Human Genome Project in 2003. Dr....
ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer
Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference.1 Previous research has suggested that radiotherapy may be of little help in this setting. The...
ASCO Wants to Hear From Your Practice—Take Part in the 2017 ASCO Practice Census
Encourage your practice to participate in the 2017 ASCO Practice Census—the only annual survey of the entire U.S. oncology practice community that aims to capture and describe changes in cancer care and oncology practice over time. The data and insights obtained from the Practice Census are...
ASCO’s New Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce
The hematology/oncology workforce continues to struggle with adequate representation of racial and ethnic minorities. To promote the development of an oncology workforce that reflects the demographics of the population it serves, ASCO has introduced its Strategic Plan for Increasing Racial &...
Enhance Your Annual Meeting Experience With Attendee Resources
Next month, more than 30,000 oncology professionals will gather in -Chicago for the 2017 ASCO Annual Meeting. This year’s theme, “Making a Difference in Cancer Care WITH YOU,” speaks to driving advances in cancer care and treatment through teamwork among clinicians, researchers, educators, and...
ASCO and Other Oncology, Medical Societies Speak Out Against White House’s Proposed Budget Cuts
On May 23, President Trump presented the White House’s fiscal year 2018 budget request, which proposes a $7.18 billion cut to the National Institutes of Health (NIH)—a budget decrease of 21%. In addition, it cuts the Center for Disease Control and Prevention’s chronic disease...
FDA Grants Priority Review to sBLA for Pembrolizumab in Recurrent or Advanced Gastric or GEJ Adenocarcinoma
The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) seeking approval for treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have already...
Ronald P. DeMatteo, MD, FACS, Named Chair of the Department of Surgery at Penn Medicine
Ronald P. DeMatteo, MD, FACS, has been named Chair of the Department of Surgery in the Perelman School of Medicine at the University of Pennsylvania. He will assume his new post July 1, 2017, and will lead a department that includes 130 faculty across 11 divisions who provide advanced patient care ...
JNCCN 360, the Source for Tumor-Specific News and Treatment Updates, Available Now
Launched during the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™, JNCCN360.org is the latest resource from the Journal of the National Comprehensive Cancer Network (JNCCN). Currently available for breast...
Complications From Thyroid Cancer Surgery More Common Than Once Thought
As thyroid cancer rates rise, more patients are having surgery to remove all or part of their thyroid. A new study by Papaleontiou et al in The Journal of Clinical Endocrinology & Metabolism suggests complications from these procedures are more common than previously believed. Overall, 6.5% of ...
AKT Inhibitor Activity in AKT1-Mutant Solid Tumors
As reported by Hyman et al in the Journal of Clinical Oncology, a basket study has shown activity of an investigational ATP-competitive pan-AKT kinase inhibitor (AZD5363) in solid tumors with AKT1 E17K mutation. Study Details In the study, 52 patients with advanced estrogen...
New ASCO Answers Fact Sheets for Your Patients
The ASCO Answers chemobrain fact sheet helps patients understand and manage the cognitive side effects of chemotherapy. Patients will learn about the causes, symptoms, management, and treatment of “chemobrain.” The ASCO Answers diarrhea fact sheet helps patients understand the causes and risks of...
Two Faculty Members From Johns Hopkins Elected to National Academy of Sciences
Johns Hopkins University faculty members Stephen B. Baylin, MD, and Robert F. Siliciano, MD, PhD, have been elected to the National Academy of Sciences in recognition of their “distinguished and continuing achievements in original research.” They are among 84 new members and 21 foreign associates ...
4 Reasons to Use Social Media at the ASCO Annual Meeting
Join the discussion: Use #ASCO17 on Twitter to follow and participate in the Annual Meeting conversation in real time. During this past year’s Annual Meeting, more than 16,000 health-care professionals, researchers, news outlets, patients, advocates, and other participants sent nearly 70,000...
ASCO Issues Recommendations for Reducing Cancer Disparities Among Sexual and Gender Minority Populations
ASCO has issued recommendations addressing the needs of sexual and gender minority populations as they relate to cancer. The recommendations, published in a policy statement in the Journal of Clinical Oncology,1 are designed to focus attention on the challenges facing the sexual and gender...
Expert Point of View: David L. Porter, MD & Jonathan S. Serody, MD
In a separate interview with The ASCO Post, David L. Porter, MD, Director of Blood and Marrow Transplantation and the Jodi Fisher Horowitz Professor in Leukemia Care Excellence at the University of Pennsylvania, Philadelphia, said: “It is encouraging that many patients with acute lymphoblastic...
Rafal Dziadziuszko, MD, PhD, Receives 2017 Heine H. Hansen Award
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) awarded the 2017 Heine H. Hansen Award to Rafal Dziadziuszko, MD, PhD, at the European Lung Cancer Conference (ELCC) 2017, which was held May 5–8 in Geneva, Switzerland. The...
Marie Bleakley, MD, PhD, Receives Research Grant in Immuno-oncology From Stand Up To Cancer
Marie Bleakley, MD, PhD, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center (Fred Hutch), has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer (SU2C). Dr. Bleakley will use the 3-year, $750,000 award to develop T-cell therapies...
Alice T. Shaw, MD, PhD, Joins LUNGevity Foundation Scientific Advisory Board
LUNGevity Foundation has announced that Alice T. Shaw, MD, PhD, joined its Scientific Advisory Board, a group of 20 world-renowned scientists and researchers who guide LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and...
Pharmaceutical Companies Collaborate in NCCN Oncology Research Program
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three studies in its first multi-industry collaborative research project, in which Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company are collaborating with NCCN to study combination...
New Chief of CHOP’s Cellular Therapy and Transplant Section
A leading pediatric oncologist at Children’s Hospital of Philadelphia (CHOP), Stephan Grupp, MD, PhD, was named Chief of the Section of Cellular Therapy and Transplant in the Hospital’s Division of Oncology. Dr. Grupp, who has researched and led groundbreaking clinical trials of an innovative...
Metastatic Urothelial Carcinoma: A Model Malignancy for Immune Checkpoint Blockade
Platinum-based combination chemotherapy became a mainstay of first-line treatment for metastatic urothelial cancer in the 1980s. With combination platinum-based regimens, 40% to 50% of patients achieve an objective response to treatment. However, aside from approximately 5% to 10% of patients who...
The Ongoing Challenges of Lung Cancer Screening
Lung cancer persistently remains the leading cause of cancer death among men and women in the United States. Only about 15% of lung cancers are diagnosed at the localized stage, when clinical intervention could markedly improve patient outcomes. For decades, lung cancer specialists and advocacy...
FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site-Agnostic Indication
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...
Neratinib in Combination With Ado‑trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Puma Biotechnology presented interim results from the phase Ib/II FB-10 clinical trial of the oral pan-HER family irreversible tyrosine kinase inhibitor neratinib given in combination with the antibody-drug conjugate ado-trastuzumab emtansine (also known as T-DM1, Kadcyla) at the 2017 American...
Abemaciclib Active in Metastatic Breast Cancer
In the single-arm phase II MONARCH 1 trial, the investigational cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib achieved an objective response in about 20% of heavily pretreated patients with metastatic hormone receptor–positive, HER2-negative breast cancer and a disease control rate of...
Key Gene Controlling Tumor Growth in Gliomas Pinpointed
Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and may strongly influence survival rates of patients. The findings, published by Edwards et al in Scientific Reports,1 may move physicians closer to their goal of better...
Henry Ford Cancer Institute Appoints Spencer C. Hoover, Vice President, Executive Director
Spencer C. Hoover, a decorated U.S. Army veteran who joined Henry Ford Health System in 2015, was appointed Vice President and Executive Director of the health system’s Henry Ford Cancer Institute and cancer care services. Mr. Hoover had previously served as Vice President of Planning and Business ...
First-in-Human Clinical Trial in Children and Young Adults With Leukemia
After phase I results of Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial, published by Gardner et al in Blood,1 showed T-cell immunotherapy to be effective in sending 93% of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into complete initial...
Study Establishes Low Risk for Contralateral Breast Cancer After Diagnosis of Ductal Carcinoma in Situ
An increasing number of women with ductal carcinoma in situ are undergoing contralateral mastectomy, but the 5-year risk of cancer in the opposite breast is only about 3%, a study from Memorial Sloan Kettering Cancer Center recently found.1 Investigators hope these numbers will dissuade women from ...
Optimizing Treatment for Elderly Patients With Glioblastoma
In 2005, Stupp and colleagues published their landmark paper demonstrating in a randomized phase III trial that the addition of temozolomide to radiation increased overall survival in patients with newly diagnosed glioblastoma. Notably, patients over age 70 years were excluded from this study.1...
